Do the investigative sites that take part in a positive clinical trial translate that evidence into practice?

American Journal of Medicine

Volumn 113, Issue 2, 2002, Pages 140-145

  Majumdar, Sumit R ^a,b   Chang, Wei Ching ^c   Armstrong, Paul W ^b,c  

^a Division of General Internal Medicine   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Virtual Coordinating Center for Global Collaborative Cardiovascular Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; EMERGENCY MEDICAL SERVICES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PILOT PROJECTS; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; STREPTOKINASE; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0037159555     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01166-X     Document Type: Article

References (24)

1. Evaluating and improving physician prescribing
2. Clinical evaluation: How does it influence medical practice?
3. The state of the art versus the state of the science. The diffusion of new medical technologies into practice
4. The evolution of clinical policies
5. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?
6. The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study
7. Scientific versus commercial sources of influence on the prescribing behavior of physicians
8. Better care and better outcomes. The continuing challenge
9. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction
10. Clinical trials and clinical practice
11. Impact of clinical trials on clinical practice: Example of thrombolysis for acute myocardial infarction
12. Translating clinical trial results into practice: The effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women
13. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: A randomized controlled trial
14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
15. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
16. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction
17. The effect of diltiazem on mortality and reinfarction after myocardial infarction
18. Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction
19. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2
20. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview
21. Geographic variation in the treatment of acute myocardial infarction. The Cooperative Cardiovascular Project
22. The management of patients who have suffered an acute myocardial infarction in a tertiary care center
23. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP)